MPD: Phenotype measures mapped to MA:0000141, spleen

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:7	Wiltshire4	immune cell quantification	BEZ235	T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:13	Wiltshire4	immune cell quantification	BEZ235	monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:27	Wiltshire4	immune cell quantification	doxorubicin	T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:41	Wiltshire4	immune cell quantification	idarubicin	B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:61	Wiltshire4	immune cell quantification	selumetinib	B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:67	Wiltshire4	immune cell quantification	selumetinib	T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:73	Wiltshire4	immune cell quantification	selumetinib	monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4

immune cell quantification

BEZ235

B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

BEZ235

T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

BEZ235

monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Filter Table Results